Antibody therapeutics with high affinity for Fc{gamma}Rs exacerbate anaphylaxis via Fc{gamma}R-mediated capture by tumor-associated myeloid cells

Background <p>Antibody therapeutics have revolutionized cancer treatment, but their use is increasingly associated with adverse events. Among these, anaphylaxis is particularly concerning due to its severity and unpredictability. Our previous studies demonstrated that repeated administration of anti-programmed death-ligand 1 antibodies to tumor-bearing mice induces antidrug antibodies (ADAs) and anaphylaxis. However, the specific characteristics of antibody therapeutics responsible for this effect…